Active Monitoring With or Without Endocrine Therapy for Low-Risk Ductal Carcinoma In SituE. Shelley Hwang, Doreen M. Agnese, Meredith Witten et al.|JAMA|2024Cited by 75
Patient-Reported Outcomes for Low-Risk Ductal Carcinoma In SituAnn H. Partridge, Kimberly Strickland, Terry Hyslop et al.|JAMA Oncology|2024Cited by 16
Time to treatment and survival in triple negative breast cancer patients receiving trimodality treatment in the United StatesKelsey E. Larson, Debra A. Pratt, SR Grobmyer et al.|Cancer Treatment and Research Communications|2018Cited by 5
Abstract GS2-06: Patient Reported Outcomes Following Active Monitoring or Surgery (+/- Radiation) for Low Risk DCIS in the Comparing an Operation to Monitoring, with or without Endocrine Therapy (COMET) Study (AFT-25)Ann H. Partridge, Shelley Hwang, Terry Hyslop et al.|Clinical Cancer Research|2025Cited by 0